ONE-WAYOngoing theme · still written in the latest filings
Pharmaceutical companies’ focus on selected areas and external licensing amid soaring new drug development costs
A structural shift in the pharmaceutical industry, driven by rising new drug development costs, as pharmaceutical companies pursue M&A, narrow their focus to priority areas, and bring in development programs from external sources.
Companies2How many companies write about this.
Threads2One company can carry more than one thread here.
PeriodFY2023-Q2 →Still being written about.
Directionflat0 helps · 0 hurts · 2 flat